skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells

Abstract

Highlights: •PARP1 siRNA enhances docetaxel’s activity against PC3 cells. •PARP1 siRNA enhances docetaxel’s activity against EGFR/Akt/FOXO1 pathway. •PARP1 siRNA and PARP1 inhibitor differently affect the phosphorylation and expression of FOXO1. -- Abstract: Though poly(ADP-ribose) polymerase 1 (PARP1) inhibitors have benefits in combination with radiotherapy in prostate cancers, few is known about the exactly role and underlying mechanism of PARP1 in combination with chemotherapy agents. Here our data revealed that inhibition of PARP1 by small interfering RNA (siRNA) could enhance docetaxel’s activity against PC3 cells, which is associated with an accelerate repression of EGF/Akt/FOXO1 signaling pathway. Our results provide a novel role of PARP1 in transcription regulation of EGFR/Akt/FOXO1 signaling pathway and indicate that PARP1 siRNA combined with docetaxel can be an innovative treatment strategy to potentially improve outcomes in CRPC patients.

Authors:
 [1]; ; ; ; ; ;  [1];  [2];  [3];  [1]
  1. Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Key Laboratory of Urology (China)
  2. Institute of Medical Radiation Biology, University of Duisburg-Essen Medical School, Essen (Germany)
  3. Department of Urology, The Affiliated Hospital of Guangdong Medical College (China)
Publication Date:
OSTI Identifier:
22242226
Resource Type:
Journal Article
Journal Name:
Biochemical and Biophysical Research Communications
Additional Journal Information:
Journal Volume: 442; Journal Issue: 1-2; Other Information: Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0006-291X
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; ADP; CHEMOTHERAPY; INHIBITION; NEOPLASMS; PATIENTS; PHOSPHORYLATION; PROSTATE; RADIOTHERAPY; RIBOSE; RNA; TRANSCRIPTION

Citation Formats

Wu, Wenqi, Kong, Zhenzhen, Duan, Xiaolu, Zhu, Hanliang, Li, Shujue, Zeng, Shaohua, Liang, Yeping, Iliakis, George, Gui, Zhiming, and Yang, Dong. Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells. United States: N. p., 2013. Web. doi:10.1016/J.BBRC.2013.11.027.
Wu, Wenqi, Kong, Zhenzhen, Duan, Xiaolu, Zhu, Hanliang, Li, Shujue, Zeng, Shaohua, Liang, Yeping, Iliakis, George, Gui, Zhiming, & Yang, Dong. Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells. United States. https://doi.org/10.1016/J.BBRC.2013.11.027
Wu, Wenqi, Kong, Zhenzhen, Duan, Xiaolu, Zhu, Hanliang, Li, Shujue, Zeng, Shaohua, Liang, Yeping, Iliakis, George, Gui, Zhiming, and Yang, Dong. 2013. "Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells". United States. https://doi.org/10.1016/J.BBRC.2013.11.027.
@article{osti_22242226,
title = {Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells},
author = {Wu, Wenqi and Kong, Zhenzhen and Duan, Xiaolu and Zhu, Hanliang and Li, Shujue and Zeng, Shaohua and Liang, Yeping and Iliakis, George and Gui, Zhiming and Yang, Dong},
abstractNote = {Highlights: •PARP1 siRNA enhances docetaxel’s activity against PC3 cells. •PARP1 siRNA enhances docetaxel’s activity against EGFR/Akt/FOXO1 pathway. •PARP1 siRNA and PARP1 inhibitor differently affect the phosphorylation and expression of FOXO1. -- Abstract: Though poly(ADP-ribose) polymerase 1 (PARP1) inhibitors have benefits in combination with radiotherapy in prostate cancers, few is known about the exactly role and underlying mechanism of PARP1 in combination with chemotherapy agents. Here our data revealed that inhibition of PARP1 by small interfering RNA (siRNA) could enhance docetaxel’s activity against PC3 cells, which is associated with an accelerate repression of EGF/Akt/FOXO1 signaling pathway. Our results provide a novel role of PARP1 in transcription regulation of EGFR/Akt/FOXO1 signaling pathway and indicate that PARP1 siRNA combined with docetaxel can be an innovative treatment strategy to potentially improve outcomes in CRPC patients.},
doi = {10.1016/J.BBRC.2013.11.027},
url = {https://www.osti.gov/biblio/22242226}, journal = {Biochemical and Biophysical Research Communications},
issn = {0006-291X},
number = 1-2,
volume = 442,
place = {United States},
year = {Fri Dec 06 00:00:00 EST 2013},
month = {Fri Dec 06 00:00:00 EST 2013}
}